FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Guardant Health's FCF Yield % or its related term are showing as below:
MEX:GH'
s FCF Yield % Range Over the Past 10 Years
Min: -18.03 Med: -2.94 Max: -0.78
Current: -1.2
During the past 10 years, the highest FCF Yield % of Guardant Health was -0.78%. The lowest was -18.03%. And the median was -2.94%.
MEX:GH's FCF Yield % is ranked better than 50.23% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.41
vs MEX:GH: -1.20
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Guardant Health FCF Yield % Related Terms
Guardant Health FCF Yield % Historical Data
* Premium members only.
The historical data trend for Guardant Health's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Guardant Health's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (MEX:GH) has a FCF Yield % of -1.20 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #107 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 49.8%.
Is Guardant Health's FCF Yield % too high?
Guardant Health's current FCF Yield % is -1.20. Based on the distribution chart, Guardant Health ranks #107 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Guardant Health has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's FCF Yield % compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #107 out of 215 companies for FCF Yield %. This puts Guardant Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Guardant Health and its competitors. Guardant Health's current FCF Yield % is -1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Guardant Health (MEX:GH) has a current FCF Yield % of -1.20. The stock's GF Value™ is MXN1,048.04, compared to a current price of MXN2,590.00 — trading 147.1% above its estimated fair value. The current FCF Yield % is -1.20. Guardant Health's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current FCF Yield % is -1.20 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 147.1% above its estimated GF Value™ of MXN1,048.04.
Key valuation signals for MEX:GH:
FCF Yield %: -1.20
GF Value™: MXN1,048.04 vs. price of MXN2,590.00 (147.1% above fair value)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
